{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-014396","form_type":"8-K","ticker":"DWTX","cik":"0001818844","company_name":"Dogwood Therapeutics, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.416362+00:00","generated_at":"2026-06-11T18:49:26.085441+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Virios Q2 net loss $1.4M ($0.08/share); cash $4.6M; FDA IMC-1 toxicology adequate; pK study planned","bullets":["Net loss $1.4M ($0.08 per share) vs $3.7M ($0.44) in Q2 2022; R&D down to $0.6M, G&A down to $0.9M.","Cash $4.6M at June 30, plus $1.4M raised via July Sales Agreement; runway at least 12 months.","FDA indicates IMC-1 chronic toxicology program adequate to support Phase 3 fibromyalgia study.","Pk/food-effect study planned for H2 2023; first Phase 3 FM study enrollment targeted for mid-2024.","IMC-2 Long-COVID: new double-blind placebo-controlled study with Bateman Horne Center; FDA meeting to discuss Phase 2."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-014396","json":"https://secwatch.observer/filing/0001558370-23-014396.json","markdown":"https://secwatch.observer/filing/0001558370-23-014396.md","text":"https://secwatch.observer/filing/0001558370-23-014396.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818844/000155837023014396/0001558370-23-014396-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818844/000155837023014396/tmb-20230810x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T18:49:26.085441+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"aca95d91fbb1cdad456ad60f6ce66f51a5e46541","claim":"Dogwood Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income $1.4 million, EPS $0.08 basic and diluted net loss per share.","evidence_excerpt":"Net loss for the second quarter of 2023 was $1.4 million, or $0.08 basic and diluted net loss per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818844/000155837023014396/0001558370-23-014396-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Net income","value":"$1.4 million"},{"label":"EPS","value":"$0.08 basic and diluted net loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}